Compare MAGN & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAGN | CUVL |
|---|---|---|
| Founded | 1864 | N/A |
| Country | United States | Australia |
| Employees | 2980 | 16 |
| Industry | Paper | Miscellaneous |
| Sector | Basic Materials | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.7M | 374.2M |
| IPO Year | 1994 | N/A |
| Metric | MAGN | CUVL |
|---|---|---|
| Price | $11.91 | $5.75 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 332.7K | 20.9K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,204,000,000.00 | N/A |
| Revenue This Year | $5.37 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 46.50 | N/A |
| 52 Week Low | $7.82 | $5.60 |
| 52 Week High | $15.52 | $8.20 |
| Indicator | MAGN | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 39.28 |
| Support Level | $11.54 | $5.70 |
| Resistance Level | $11.91 | $6.07 |
| Average True Range (ATR) | 0.36 | 0.16 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 45.87 | 35.42 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.